Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2026

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Adibelimab

Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks)

All Listed Sponsors

lead

Second Affiliated Hospital of Xi'an Jiaotong University

OTHER

NCT06336954 - Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure | Biotech Hunter | Biotech Hunter